Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE versus COLESTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE versus COLESTID.
CHOLESTYRAMINE vs COLESTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
5-10 g orally once or twice daily, maximum 30 g/day.
None Documented
None Documented
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant